At SfN 2017, some of the lesser-known tau toxicities came in for deep scrutiny.
At SfN 2017, scientists advanced the idea that bacteria teeming in a person’s digestive tract could influence both pathology and symptoms of diseases such as Alzheimer’s.
Why, hello tau! Convergence of PET and EEG research affirms that sleeping well is crucial to memory consolidation and curbing Alzheimer’s-related proteins.
Novel ways to control tau captured the imaginations of scientists at the Society for Neuroscience annual meeting.
At recent CTAD conference, Rachelle Doody called on her colleagues to learn from failures and work together to support better drug evaluation studies.
Null results ended the development of the neuroprotective drugs edonerpic and abeotaxane, the AMPA receptor modulator S47445, and the dietary formulation tricaprilin.
Besides the big-gun antibodies and BACE inhibitors, smaller, lesser-known drug programs are inching their way through the clinical trials pipeline. As is often the case, Phase 1 seems encouraging.
Phase 1 trial tests the rejuvenating effects of young blood, while albumin replacement may offer its own benefits.
In a Phase 2 trial in nursing home residents with Alzheimer’s, this new drug mitigated symptoms safely, without detriment to cognition.
Gradually raising the dose of this therapeutic antibody appears to ease the risk of brain inflammation.
Presented at CTAD, BACE inhibitor’s efficacy and safety results in mild to moderate AD were encouraging to some clinicians, vaguely disquieting to others.
Recruitment, recruitment, recruitment: Registries get creative in how they promote research engagement and fill prevention trials.
Who doesn’t dread hours of testing at a clinic? Innovation needed! Learn about frequent “burst” testing via mobile app, and a digital pen that captures more information than the old paper-and-pencil test.
Clinical validation is showing automated Elecsys, Lumipulse assays to be reliable and predictive. The story on blood tests has turned from non-starter to intensely promising for broad-based screening.
Tau’s apparent lockstep with cognitive decline dominated the PET conversation. Piramal flaunted data, and Merck/Cerveau are close behind. A first stab at imaging synapses in the hippocampus drew notice, too.